Non-Profits Create Next-Generation Medicines that Treat Ultra-Rare Diseases

October 8th, 2021|Categories: Perspectives on Current Science|

Hundreds of millions of people worldwide are living with a rare disease. Most rare diseases do not currently have a cure. So, once diagnosed with a rare disease, most patients and their families are merely given strategies to manage the disease symptoms and try ...

Oligonucleotides Safely Cross the Blood-Brain Barrier to Knock Down Gene Expression

September 13th, 2021|Categories: Perspectives on Current Science|

Neurodegenerative diseases, brain tumors, and infectious diseases and inflammatory conditions that impact the brain wreak havoc on a person’s health and are notoriously difficult to treat. Oligonucleotide drugs could provide solutions to many pathological brain conditions if certain challenges could be overcome. Researchers at ...

OTS President’s Paper Pick – August 2021

August 9th, 2021|Categories: Presidents Pick, Perspectives on Current Science|

By: Annemieke Aartsma-Rus, Ph.D. The paper information: CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis Julian D Gillmore, Ed Gane, Jorg Taube, Justin Kao, Marianna Fontana, Michael L Maitland, Jessica Seitzer, Daniel O’Connell, Kathryn R Walsh, Kristy Wood, Jonathan Phillips, Yuanxin Xu, Adam Amaral, Adam ...

Lipid Nanoparticles: Nanomedicine’s Triumph

August 6th, 2021|Categories: Perspectives on Current Science|

Oligonucleotide therapeutics have been making headlines this past year, between the groundbreaking new mRNA vaccines and the recent news of phenomenal interim results for Intellia’s investigational genome editing treatment for ATTR amyloidosis. Neither of these would have been possible without a lesser-known component – ...

A Momentous CRISPR Milestone was Achieved with Remarkable Results

August 1st, 2021|Categories: Perspectives on Current Science, Featured Perspectives On Current Science|

Intellia Therapeutics and Regeneron Pharmaceuticals’ recent announcement is a major milestone worth celebrating. They shared interim data from the first ever human study using systemically administered CRISPR as a gene editing therapy. Early results that surpassed expectations show that not only is the CRISPR-based therapy ...

Oligonucleotide Therapeutics – Restoring Sight to the Blind

June 28th, 2021|Categories: Perspectives on Current Science|

Vision is one of our most priceless senses. Without it, we miss out on precious visuals, such as witnessing a child’s face light up with joy or seeing a glorious sunset, and even the important relational activity of reading the expressions on someone’s face ...

Oligonucleotides Provide Hope for the Treatment of Duchenne Muscular Dystrophy

May 20th, 2021|Categories: Perspectives on Current Science|

Imagine if your muscles began weakening for no apparent reason. Then, after an ongoing search for a diagnosis, you learn that you have a disease in which your muscles would progressively waste away and become weaker until you would no longer be able to ...

Go to Top